Deal: Brazil's EMS and India's Torrent Pharma vying for Sanofi's generic drugs

Brazilian drugs firm EMS and Indian rivalTorrent Pharmahave emerged as the only industry bidders for Sanofi's generic drugs unit, battling a series of buyout funds for an asset worth as much as $2.4 billion, sources familiar with the matter told Reuters.

Deal: Blackstone, Strides, Nectar lead race for Orchid Pharma

Strides Shasun, Nectar Lifesciencesand private equity firm Blackstone have emerged as frontrunners for bankrupt Orchid Pharma with Aurobindo and Dr Reddy's backing out, said two senior officials with knowledge of the development.

Nagpur-based ZIM Labs plans Rs. 220 crore investment to foray into Europe, US markets

The Nagpur-based ZIM Laboratories, a leading provider of new drug delivery systems, has embarked on an initiative to expand its presence in Europe and US markets over the next three years with an investment of Rs. 220 crore and broaden portfolio of novel and differentiated drug delivery solutions.

Divis to spend Rs 300 crore on expansion plans in 2018

Drug firm Divis Laboratoriesis focussed on expanding capacities of existing plants, even as its proposed plant at Kakinada, Andhra Pradesh ran into rough weather, a senior official of the city-based drug maker said here today.

Deal: Carlyle Group leads race for 15 per cent in Mankind Pharmaceuticals

Carlyle Group is leading the race to invest as much as $500 million for a 15% stake in Mankind Pharmaceuticals in what could become one of the largest private equity transactions in the pharma space

Ipca Laboratories buys US API developer Pisgah Labs for $9.65 million

Ipca Laboratories Ltd on Wednesday said that its two subsidiaries have fully acquired US-based Pisgah Labs Inc. for $9.65 million.

Biocon teams up with Sandoz for next-gen Biosimilars

Biocon and Sandoz, the generic drug division of Novartis, have formed a partnership to develop, manufacture and sell affordable copies of biologic drugs in immunology and oncology globally.

Torrent Pharma buys US firm Bio-Pharm

Torrent Pharmaceuticals has acquired Bio-Pharm, a generic and overthe-counter drugmaker based in Levittown, Pennsylvania, for an undisclosed sum.

Trump effect: Indian pharma majors rush to ‘Make in America’

US President Donald Trump's 'Make in America' pledge may have spooked many, but Indian pharmaceutical companies are optimistic.

Piramal Enterprises explores re-entry into Indian formulations business

 Piramal Enterprises is evaluating a return to the domestic formulation market after a non-compete agreement with Abbottexpires this year, said people familiar with the plan. 

Indian, Chinese drugmakers eye Sanofi's European generics unit for $2B deal

As Sanofi looks to reshape itself and offload its European generics business, it's reportedly getting some interest around the globe for an outfit that analysts believe could fetch $2 billion. 

Pharma companies focus on limited competition drugs(complex product) for the US market

Wednesday Alok Sonig, vice-president (Global), Dr Reddy’s Laboratories, will be presenting his company’s strategy for limited-competition products at the ongoing JP Morgan Healthcare Conference in San Francisco.

Market Now: Pharma stocks in pain; Divi's Lab, Cadila top losers

Most of the pharma stocks including Divi's Laboratories (down 1.90 per cent), Cadila Healthcare (down 1.53 per cent), GlaxoSmithKline Pharmaceuticals (down 1.38 per cent) and Piramal Enterprises (down 1.09 per cent) were trading down in afternoon trade on Tuesday. 

Dr. Reddy’s Investor Presentation – Nov 2017

Click here for detail of  Dr. Reddy’s Investor Presentation – Nov 2017

Sun pharma: Full annual report, key trends for the next five years and Pharmaceuticals spending: 2016-2017

KEY PERFORMANCE INDICATORS

GLOBAL PHARMACEUTICAL INDUSTRY The global spending on medicines is expected to reach nearly US$ 1.5 Trillion by 2021. This is an increase of nearly US$ 370 Billion from the 2016 estimated spending level, representing a CAGR of 4-7%.The two main drivers of this growth will be introduction of new innovative products in the developed markets and increased volumes of branded generics in the emerging markets. Click here for full report

GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER

Financial highlights             

·         Sales growth in Pharmaceuticals and Consumer Healthcare; Vaccines sales flat    

·         Pharmaceuticals sales £4.2 billion +3% AER, +2% CER; Vaccines £1.7 billion +5% AER, flat at CER; Consumer Healthcare £2.0 billion +5% AER, +2% CER    

·         Improved Total operating margin of 23.9% (+4.9 points, including 0.2 points currency benefit) and EPS (24.8p), primarily reflecting reduced transaction-related charges related to valuations of Consumer Healthcare and HIV businesses    

·         Improved Adjusted Group operating margin of 31.5% (+1.0 point, no currency effect) primarily reflecting leverage from sales growth, focus on costs and benefits of restructuring. Pharmaceuticals 34.0% (-0.3 points, no currency effect); Vaccines 41.3% (+1.6 points, including 0.3 points adverse currency effect); Consumer Healthcare 20.0% (+3.9 points, including 1.3 points currency benefit)   Click here to get full report

Financial Results - Novartis India September 30, 2017

Click here to find the statement of financial result of Novartis India for September 2017

Financial Results: NOVARTIS INDIA LIMITED ANNUAL REPORT 2016-17

Summary of the Financial Results 

Segment-wise operational performance 
 The Pharmaceuticals business registered Net Revenue from Operations of ` 6,562.3 million representing a decrease of 4.9 percent over the previous year. Expansion of National List of Essential Medicines (NLEM) has led to increase in the scope of drugs subject to price control.

Bussines updates: I​​ndia imported APIs worth Rs 18,372.54 crore in 2016-17

India imported Active Pharmaceutical Ingredients worth Rs 18,372.54 crore in 2016-17, of which the maximum was from China, Parliament was informed today. 

Acquisition of week: Takeda to acquire Belgium-based biopharma company, TiGenix for EUR 520 million

Takeda Pharmaceutical Company Limited has announced its intention to acquire TiGenix NV, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, and as a result has entered into an offer and support agreement with TiGenix which provides for a recommended potential voluntary public takeover bid for TiGenix.